Next-generation Immunotherapies for Cancer

Our laboratory focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapy with the goal of rationally design innovative next-generation immunotherapies for relapsing/refractory leukemia and lymphoma. 


For more information, please visit the links below.

 CCI Faculty Website            Perelman School of Medicine Faculty Page


If you would like to make a monetary contribution, please see the link below. Thank you in advance for your support! 

Select "Special Reason" and leave a note: “Donation to fund Dr. Marco Ruella’s research.

 Giving to Penn: The Fund for the Abramson Cancer Center